Structure-based optimization of aldose reductase inhibitors originating from virtual screening

Area of Science:

• Biochemistry
• Medicinal Chemistry
• Pharmacology

Background:

• Diabetes mellitus is a global health issue with severe microvascular complications like nephropathy, neuropathy, and retinopathy.
• Sorbitol accumulation, mediated by aldose reductase (ALR2), is a key factor in developing these diabetic complications.
• Targeting ALR2 with inhibitors is crucial for preventing long-term diabetes-related damage.

Purpose of the Study:

• To design and synthesize novel aldose reductase inhibitors using a structure-based approach.
• To identify compounds with potent inhibitory activity against human aldose reductase.
• To elucidate the binding mode of these inhibitors through crystal structure analysis.

Main Methods:

• Virtual screening of compounds using the crystal structure of human aldose reductase complexed with an inhibitor.
• Lead structure simplification and development of synthetic pathways from commercially available materials.
• In vitro enzymatic assays to determine inhibitory activity (IC50 values) and crystal structure analysis of potent derivatives.

Main Results:

• Virtual screening identified initial compounds with low micro- to submicromolar IC50 values.
• Newly synthesized compounds demonstrated significantly improved inhibitory activity, reaching the nanomolar range.
• Crystal structure analysis provided detailed insights into the binding interactions of the most potent inhibitors with ALR2.

Conclusions:

• Structure-based design effectively yielded highly potent aldose reductase inhibitors.
• The developed inhibitors represent promising candidates for preventing diabetic microvascular complications.
• Further investigation into these novel inhibitors could lead to new therapeutic strategies for diabetes management.